CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Nov. 12, 2018—NeuMoDx Molecular announced the U.S. launch of its FDA 510(k)-cleared NeuMoDx 288 Molecular System and its FDA-listed NeuMoDx 96 Molecular System at the Association for Molecular Pathology annual meeting in San Antonio.
The fully automated systems integrate the molecular diagnostic process, from extraction to detection, with the first result available in approximately one hour. The analyzers offer operators the ability to load up to 288 and 96 patient samples, respectively, in a continuous, random-access workflow, resulting in on-demand, high-throughput sample processing with a walkaway time of up to eight hours.
Pages: 1 2